{"id":409063,"date":"2019-08-27T00:00:00","date_gmt":"2019-08-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0017-2018-biopharma-psoriasis-access-and-reimbursement-us-2018\/"},"modified":"2026-03-31T10:46:27","modified_gmt":"2026-03-31T10:46:27","slug":"acreim0017-2018-biopharma-psoriasis-access-and-reimbursement-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0017-2018-biopharma-psoriasis-access-and-reimbursement-us-2018\/","title":{"rendered":"Psoriasis | Access and Reimbursement | US | 2018"},"content":{"rendered":"<p>MARKET OUTLOOK<\/p>\n<p>In the past decade, AbbVie\u2019s Humira and Amgen\u2019s Enbrel tumor necrosis factor-alpha (<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1) inhibitors and Janssen\u2019s interleukin (<abbr title=\"interleukin\">IL<\/abbr>)-12\/23 inhibitor Stelara have been leading the U.S. psoriasis biologics market. However, the recent wave of U.S. approvals for novel psoriasis agents\u2014including Celgene\u2019s Otezla, three\u00a0<abbr title=\"interleukin\">IL<\/abbr>-17 inhibitors, and two\u00a0<abbr title=\"interleukin\">IL<\/abbr>-23 inhibitors\u2014is altering the market landscape. The oral agent Otezla has been successfully carving out a space in biologics-naive patients. The more-effective biologics, Novartis\u2019s Cosentyx and Eli Lilly\u2019s Taltz<abbr title=\"interleukin\">IL<\/abbr>-17 inhibitors, are threatening the first-line dominance of\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors, and Janssen\u2019s\u00a0<abbr title=\"interleukin\">IL<\/abbr>-23 inhibitor Tremfya is likely to follow. With the recent entry of biosimilars and another\u00a0<abbr title=\"interleukin\">IL<\/abbr>-23 inhibitor in late-phase development, marketers of psoriasis therapies will learn how they can best overcome the formulary and uptake challenges facing current and emerging therapies in this increasingly competitive market.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>What are the current patient share leaders among psoriasis biologics\/Otezla, and which psoriasis agents do physicians and payers perceive as performing best on specific clinical and market access factors?<\/li>\n<li>How do payers cover\/anticipate covering biosimilar versions of infliximab (Pfizer\u2019s Inflectra, Merck\u2019s Renflexis) and adalimumab (Amgen\u2019s Amgevita), and what are physicians\u2019 expected prescribing behaviors of biosimilars?<\/li>\n<li>What are physician perceptions of emerging biologics, such as risankizumab, and how do payers anticipate covering these novel agents? How are recent entrants to the market faring in terms of payer coverage and restrictions?<\/li>\n<li>What pharmacoeconomic models and data do payers value for examining the cost and efficacy impact of novel psoriasis agents?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p>Access &#038; Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.<\/p>\n","protected":false},"template":"","class_list":["post-409063","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409063","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409063\/revisions"}],"predecessor-version":[{"id":576615,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/409063\/revisions\/576615"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=409063"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}